The Food and Drug Administration yesterday released a blueprint for educating health care providers that treat or monitor patients with pain under its forthcoming Risk Evaluation and Mitigation Strategy for companies that make opioid pain relievers. Accredited continuing education providers will use the blueprint to develop educational materials and activities for the REMS. FDA Commissioner Scott Gottlieb, M.D., said the revised blueprint includes more information on pain management and pharmacologic treatments for pain, including non-opioid pain relievers. In other news, FDA said it is working with manufacturers on safer packaging for Imodium A-D (loperamide) because some people addicted to opioids are taking the over-the-counter anti-diarrhea drug at dangerously high doses to manage withdrawal or achieve euphoric effects. Taking more than prescribed or listed on the label can cause severe heart rhythm problems or death.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…